ABL Bio Inc. (KOSDAQ:298380)
190,500
+500 (0.26%)
Mar 20, 2026, 3:30 PM KST
ABL Bio Market Cap
ABL Bio has a market cap or net worth of 10.67 trillion as of March 20, 2026. Its market cap has increased by 464.97% in one year.
Market Cap
10.67T
Enterprise Value
10.61T
Revenue
79.35B
Ranking
n/a
PE Ratio
n/a
Stock Price
190,500.00
Market Cap Chart
Since December 19, 2018, ABL Bio's market cap has increased from 608.61B to 10.67T, an increase of 1,652.45%. That is a compound annual growth rate of 48.40%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 20, 2026 | 10.67T | -3.26% |
| Dec 30, 2025 | 11.03T | 663.70% |
| Dec 30, 2024 | 1.44T | 22.53% |
| Dec 28, 2023 | 1.18T | 7.19% |
| Dec 29, 2022 | 1.10T | 5.54% |
| Dec 30, 2021 | 1.04T | -27.59% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 19, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Samsung Biologics | 74.11T |
| Celltrion | 44.21T |
| Sam Chun Dang Pharm. | 21.09T |
| ALTEOGEN | 18.91T |
| Samsung Epis Holdings | 13.74T |
| Peptron | 8.07T |
| LigaChem Biosciences | 7.75T |
| SK Biopharmaceuticals | 7.72T |